Regeneron Pharmaceuticals Stock: Shares Climb 4.6% Boosted by Favorable Analyst Recommendations
The American pharmaceutical company Regeneron Pharmaceuticals ended the January 7th session with a notable performance on Wall Street. The stock gained 4.6% in a context marked by several analyst recommendation upgrades. The stock now shows a weekly increase of 5.23%.
Closing Performance and Market Context
The biopharmaceutical group's stock closed at $812.27 on Tuesday, marking a 4.6% increase from the previous session. This rise is part of a generally well-oriented market, with the Nasdaq gaining 0.78% to finish at 24,978.56 points. Trading volume for the stock reached 1,258,935 shares, representing 1.2% of the group's market capitalization, a level of turnover indicating sustained investor interest. Over a broader horizon, Regeneron's stock has shown an annual performance of 11.22%, a rise that is less than its benchmark index which has increased by 26.15% over the same period. The past week has been particularly favorable for the stock with a gain of 5.23%, placing the value on a short-term upward trajectory.
Analyst Upgrades and Price Target Adjustments
This performance comes after BofA Global Research upgraded its recommendation on the stock from 'underperform' to 'buy'. The brokerage also raised its price target from $627 to $860, representing an approximate 11% upside potential from the last closing price. BofA Global Research justifies this change in stance with a more favorable outlook on Eylea SD, the company's new version of its ophthalmic medication, following recent updates to its regulatory labeling.
